STOCK TITAN

Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that multiple abstracts on REBLOZYL® (luspatercept-aamt) will be presented at the upcoming 2021 European Hematology Association (EHA2021) Virtual Congress, to be held from June 9-17.

Of particular note, results from the BEYOND Phase 2 trial of luspatercept in adults with non-transfusion dependent beta-thalassemia will be presented on Friday, June 11th, during the Presidential Symposium, which honors the top six research papers submitted for presentation at the meeting.

“It’s a privilege to have such a prominent platform from which to share exciting new data on the effects of luspatercept in a patient population long in need of new therapeutic options,” said Habib Dable, President and Chief Executive Officer of Acceleron. “Moreover, it’s quite gratifying to present additional research that helps further establish luspatercept’s efficacy and safety profile.”

Presentations at EHA2021

Title:

The BEYOND Study: Results of a Phase 2, double-blind, randomized, placebo-controlled multi-center study of luspatercept in adult patients with non-transfusion dependent beta-thalassemia – Abstract: S101

 

 

Session:

Presidential Symposium

Date:

June 11, 2021

Time:

4:00 p.m. to 5:30 p.m. CEST

 

 

Title:

Fewer red blood cell transfusion units and visits across baseline transfusion burden levels in patients with beta-thalassemia treated with luspatercept in the Phase 3 BELIEVE trial – Abstract: e-Poster 1304

 

 

Session:

Thalassemias

 

 

Title:

Long-term efficacy and safety outcomes in the Phase 2 study of luspatercept in beta-thalassemia – Abstract: e-Poster 1305

 

Session:

Thalassemias